Download PDF
Thromb Haemost 2011; 105(05): 925-927
DOI: 10.1160/TH10-11-0724
Letters to the Editor
Schattauer GmbH

As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan

Akitada Ichinose
1   Department of Molecular Patho-Biochemistry & -Biology, Yamagata Univiversity School of Medicine, Yamagata, Japan
,
Masayoshi Souri
1   Department of Molecular Patho-Biochemistry & -Biology, Yamagata Univiversity School of Medicine, Yamagata, Japan
,
the Japanese collaborative research group on “Acquired haemorrha-philia due to factor XIII deficiency” › Author Affiliations
Further Information

Publication History

Received: 13 November 2010

Accepted after minor revision: 14 January 2011

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

 

1 A list of groupup members is given in the Appendix.


2 happening frequently in clinical scenes, even in the official journal of the International Society of Thrombosis and Hemostasis as well as in PubMed.


3 detailed characterisation of their antibodies will be reported elsewhere in the future.


 

  • References

  • 1 Lorand L. Acquired inhibitors of fibrin stabilization: A class of hemorrhagic disorders of diverse origins. In: Anticoagulants, Physiologic, Pathologic and Pharmacologic. Boca Raton, FL: CRC Press; 1994. pp. 169-191.
    Google Scholar
  • 2 Egbring R, Kröniger A, Seitz R. Erworbene Inhibitoren gegen Faktor XIII. Hämostaseologie 1996; 16: 174-179.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Teruya J, Kinoshita T, Yoshimura Y. et al. An inhibitor to factor XIII interacting with its activated catalytic subunit. Rinsho Ketsueki 1986; 27: 1680-1687.
    PubMedGoogle Scholar
  • 4 Nakamura S, Kato A, Sakata Y. et al. Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-319.
    CrossrefPubMedGoogle Scholar
  • 5 Lorand L, Velasco PT, Hill JM. et al. Intracranial hemorrhage in systemic lupus erythematosus associated with an autoantibody against actor XIII. Thromb Haemost 2002; 88: 919-923.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Nijenhuis AV, van Bergeijk L, Huijgens PC. et al. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica 2004; 89: e46-e48.
    PubMedGoogle Scholar
  • 7 Miesbach W. Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Thromb Haemost 2005; 93: 1001-1003.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lim W, Moffat K, Hayward CP. Prophylactic and peri-operative replacement therapy for acquired factor XIII deficiency. J Thromb Haemost 2004; 2: 1017-1019.
    CrossrefPubMedGoogle Scholar
  • 9 Ajzner E, Schlammadinger A, Kerényi A. et al. Severe bleeding complications caused by an autoanti-body against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009; 113: 723-725.
    CrossrefPubMedGoogle Scholar
  • 10 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 200-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Collins PW, Hirsch S, Baglin TP. et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 1870-1877.
    CrossrefPubMedGoogle Scholar
  • 12 Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-1520.
    PubMedGoogle Scholar
  • 13 Ishida F, Okubo K, Ito T. et al. Spontaneous regression of the inhibitor against the coagulation factor XIII A subunit in acquired factor XIII deficiency. Thromb Haemost 2010; 104: 1284-1285.
    Article in Thieme ConnectPubMedGoogle Scholar